Short Interest in Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) Grows By 30.5%

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) was the target of a significant increase in short interest in April. As of April 15th, there was short interest totalling 3,810,000 shares, an increase of 30.5% from the March 31st total of 2,920,000 shares. Based on an average trading volume of 1,040,000 shares, the short-interest ratio is presently 3.7 days. Approximately 15.6% of the company’s shares are sold short.

Reviva Pharmaceuticals Price Performance

NASDAQ RVPH opened at $0.87 on Friday. The stock has a market capitalization of $40.52 million, a price-to-earnings ratio of -0.78 and a beta of 0.05. Reviva Pharmaceuticals has a 1-year low of $0.49 and a 1-year high of $4.28. The business’s fifty day moving average price is $0.93 and its 200-day moving average price is $1.37.

Reviva Pharmaceuticals (NASDAQ:RVPH) last posted its quarterly earnings data on Monday, March 31st. The company reported ($0.15) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.07. Equities research analysts anticipate that Reviva Pharmaceuticals will post -0.97 EPS for the current year.

Institutional Investors Weigh In On Reviva Pharmaceuticals

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. BluePointe Capital Management LLC boosted its stake in Reviva Pharmaceuticals by 354.7% in the 1st quarter. BluePointe Capital Management LLC now owns 47,185 shares of the company’s stock worth $45,000 after purchasing an additional 36,807 shares during the period. Tang Capital Management LLC bought a new position in Reviva Pharmaceuticals during the fourth quarter valued at approximately $308,000. Cornerstone Select Advisors LLC purchased a new position in Reviva Pharmaceuticals during the 4th quarter valued at approximately $32,000. Ameriprise Financial Inc. bought a new stake in Reviva Pharmaceuticals in the 4th quarter worth approximately $84,000. Finally, Tower Research Capital LLC TRC raised its holdings in shares of Reviva Pharmaceuticals by 848.8% during the 4th quarter. Tower Research Capital LLC TRC now owns 26,775 shares of the company’s stock worth $48,000 after acquiring an additional 23,953 shares in the last quarter. Institutional investors own 63.18% of the company’s stock.

Wall Street Analyst Weigh In

RVPH has been the topic of several research reports. D. Boral Capital restated a “buy” rating and set a $8.00 price target on shares of Reviva Pharmaceuticals in a research report on Thursday, April 24th. Roth Mkm started coverage on shares of Reviva Pharmaceuticals in a report on Friday, January 10th. They set a “buy” rating and a $7.00 target price for the company. Maxim Group upgraded Reviva Pharmaceuticals from a “hold” rating to a “buy” rating and set a $7.00 price target on the stock in a research note on Friday, January 10th. HC Wainwright lowered their price objective on Reviva Pharmaceuticals from $14.00 to $11.00 and set a “buy” rating for the company in a research note on Wednesday, January 22nd. Finally, Roth Capital raised shares of Reviva Pharmaceuticals to a “strong-buy” rating in a research report on Friday, January 10th. Five equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Buy” and an average target price of $10.00.

Reviva Pharmaceuticals Company Profile

Reviva Pharmaceuticals Holdings, Inc, a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis.